The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus
Open accessAbstract
Cystic fibrosis (CF) is the most common lethal hereditary disorder with autosomal recessive heredity in caucasians. The majority of CF patients suffer from chronic respiratory infection with the opportunistic bacterial pathogen Pseudomonas aeruginosa. No consensus among clinicians has been reached so far concerning antibiotic treatment against P. aeruginosa in CF patients. Consensus answers to 24 important questions in this context, based on current evidence, are presented, given by a panel of 34 European experts. Questions addressed and answered are: The diagnosis of P. aeruginosa lung colonization in CF; The impact of P. aeruginosa on the clinical state of CF patients; The assessment of P. aeruginosa susceptibility against antibiotics and the importance of these results for the clinician; The use of monotherapy versus combination therapy; The development of microbial resistance; The achievement of optimal airway concentrations; The effects of subinhibitory concentrations of antibiotics on P. aeruginosa; Statements on the pharmacokinetics of antibiotics in CF patients; Recommendations for doses and dosing intervals and length of treatment regimens; and Toxic side effects due to repeated antibiotic therapy was addressed. The expert panel answered further questions on the use of fluoroquinolones in children with CF, on the administration of nebulized antibiotics and whether prevention of P. aeruginosa lung colonization is possible in CF using antibiotic therapy. Problems of antibiotic therapy at home and in the hospital were addressed, a consensus statement on regular maintenance treatment, or treatment on demand, was given and different routes of administration of antibiotics were recommended for different clinical situations. Finally, the factors which determine the choice of the antibiotic, the dosage, and the duration of the treatment in cystic fibrosis patients were addressed and the design of future antibiotic studies in the context of Pseudomonas aeruginosa lung infection in cystic fibrosis patients were recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ceri, H., Olson, M. E., Stremick, C., Read, R. R., Morck, D., & Buret, A. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.6.1771-1776.1999 · Cited by 2,155
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., Pepe, M. S., Quan, J. M., Otto, K. L., Montgomery, A. B., Williams-Warren, J., Vasiljev-K, M., Borowitz, D., Bowman, C. M., Marshall, B. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400104 · Cited by 1,300
Early pulmonary inflammation in infants with cystic fibrosis.
Khan, T. Z., Wagener, J. S., Bost, T., Martinez, J., Accurso, F. J., & Riches, D. W. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.4.7697234 · Cited by 1,263
Matsui, H., Grubb, B. R., Tarran, R., Randell, S. H., Gatzy, J. T., Davis, C. W., & Boucher, R. C. (1998) · Cell · doi:10.1016/s0092-8674(00)81724-9 · Cited by 1,169
Nickel, J. C., Ruseska, I., Wright, J. B., & Costerton, J. W. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.27.4.619 · Cited by 889
Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.
Shak, S., Capon, D. J., Hellmiss, R., Marsters, S. A., & Baker, C. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.23.9188 · Cited by 707
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
Valerius, N. H., Koch, C., & Høiby, N. (1991) · The Lancet · doi:10.1016/0140-6736(91)91446-2 · Cited by 475
Self-citationFrederiksen, B., Koch, C., & Høiby, N. (1997) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(199705)23:5<330::aid-ppul4>3.0.co;2-o · Cited by 473
Self-citationLower Airway Inflammation in Infants and Young Children with Cystic Fibrosis
ARMSTRONG, D. S., GRIMWOOD, K., CARLIN, J. B., CARZINO, R., GUTIÈRREZ, J. P., HULL, J., OLINSKY, A., PHELAN, E. M., ROBERTSON, C. F., & PHELAN, P. D. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.4.96-11058 · Cited by 467
Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., Dorkin, H. L., Eisenberg, J. D., Gibson, R. L., Harwood, I. R., Kravitz, R. M., Schidlow, D. V., Wilmott, R. W., Astley, S. J., McBurnie, M. A., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306173282403 · Cited by 458
Cited by
Antibiotic resistance of bacterial biofilms
Høiby, N., Bjarnsholt, T., Givskov, M., Molin, S., & Ciofu, O. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.12.011 · Cited by 3,225
Self-citationPathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Gibson, R. L., Burns, J. L., & Ramsey, B. W. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200304-505so · Cited by 1,633
Lung Infections Associated with Cystic Fibrosis
Lyczak, J. B., Cannon, C. L., & Pier, G. B. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.194-222.2002 · Cited by 1,628
Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence
Moradali, M. F., Ghods, S., & Rehm, B. H. A. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00039 · Cited by 1,537
O'Sullivan, B. P., & Freedman, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60327-5 · Cited by 1,320
British Thoracic Society guideline for non-CFbronchiectasis
Pasteur, M. C., Bilton, D., Hill, A. T., & on behalf of the British Thoracic Society Bronchiectasis (non-CF) Guideline Group (2010) · Thorax · doi:10.1136/thx.2010.136119 · Cited by 1,046
The clinical impact of bacterial biofilms
Høiby, N., Ciofu, O., Johansen, H. K., Song, Z., Moser, C., Jensen, P. Ø., Molin, S., Givskov, M., Tolker‐Nielsen, T., & Bjarnsholt, T. (2011) · International Journal of Oral Science · doi:10.4248/ijos11026 · Cited by 894
Self-citationRatjen, F., & Döring, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12567-6 · Cited by 885
Self-citationThe Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections
Driscoll, J. A., Brody, S. L., & Kollef, M. H. (2007) · Drugs · doi:10.2165/00003495-200767030-00003 · Cited by 884
Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations
Flume, P. A., Mogayzel, P. J., Robinson, K. A., Goss, C. H., Rosenblatt, R. L., Kuhn, R. J., Marshall, B. C., & and the Clinical Practice Guidelines for Pulmonary Therapies Committee (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200812-1845pp · Cited by 738
ESCMID∗ guideline for the diagnosis and treatment of biofilm infections 2014
Høiby, N., Bjarnsholt, T., Moser, C., Bassi, G. L., Coenye, T., Donelli, G., Hall-Stoodley, L., Holá, V., Imbert, C., Kirketerp-Møller, K., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.10.024 · Cited by 726
Self-citationAdaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective
Folkesson, A., Jelsbak, L., Yang, L., Johansen, H. K., Ciofu, O., Høiby, N., & Molin, S. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2907 · Cited by 715
Self-citationLee, T. W. R., Brownlee, K. G., Conway, S. P., Denton, M., & Littlewood, J. M. (2003) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(02)00141-8 · Cited by 713
Self-citationBryers, J. D. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21838 · Cited by 700
Winstanley, C., O’Brien, S., & Brockhurst, M. A. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.01.008 · Cited by 689
Pseudomonas Aeruginosa Biofilms in Cystic fibrosis
H⊘iby, N., Ciofu, O., & Bjarnsholt, T. (2010) · Future Microbiology · doi:10.2217/fmb.10.125 · Cited by 666
Self-citationBacterial Resistance: Origins, Epidemiology, and Impact
Livermore, D. M. (2003) · Clinical Infectious Diseases · doi:10.1086/344654 · Cited by 586
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium
Mesaros, N., Nordmann, P., Plésiat, P., Roussel-Delvallez, M., Van Eldere, J., Glupczynski, Y., Van Laethem, Y., Jacobs, F., Lebecque, P., Malfroot, A., et al. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01681.x · Cited by 585
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria
Li, J., Nation, R. L., Milne, R. W., Turnidge, J. D., & Coulthard, K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.10.001 · Cited by 571
Curran, B., Jonas, D., Grundmann, H., Pitt, T., & Dowson, C. G. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.12.5644-5649.2004 · Cited by 509
Standards of care for patients with cystic fibrosis: a European consensus
Kerem, E., Conway, S., Elborn, S., & Heijerman, H. (2005) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2004.12.002 · Cited by 477
Self-citationNutrition in patients with cystic fibrosis: a European Consensus
Sinaasappel, M., Stern, M., Littlewood, J., Wolfe, S., Steinkamp, G., Heijerman, H. G. M., Robberecht, E., & Döring, G. (2002) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(02)00032-2 · Cited by 477
Self-citationTreatment of lung infection in patients with cystic fibrosis: Current and future strategies
Döring, G., Flume, P., Heijerman, H., & Elborn, J. S. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.10.004 · Cited by 474
Self-citationTreatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa
Rossolini, G. M., & Mantengoli, E. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01161.x · Cited by 395
Towards diagnostic guidelines for biofilm-associated infections
Hall-Stoodley, L., Stoodley, P., Kathju, S., Høiby, N., Moser, C., William Costerton, J., Moter, A., & Bjarnsholt, T. (2012) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2012.00968.x · Cited by 357
Self-citationGuidelines for Evaluating Chronic Cough in Pediatrics
Chang, A. B., & Glomb, W. B. (2006) · Chest · doi:10.1378/chest.129.1_suppl.260s · Cited by 356
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Langton Hewer, S. C., & Smyth, A. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004197.pub4 · Cited by 324
Self-citationSaiman, L. (2003) · American Journal of Infection Control · doi:10.1067/mic.2003.78 · Cited by 307
Ciofu, O., Tolker-Nielsen, T., Jensen, P. Ø., Wang, H., & Høiby, N. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.11.017 · Cited by 306
Self-citationEarly intervention and prevention of lung disease in cystic fibrosis: a European consensus
Döring, G., & Hoiby, N. (2004) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2004.03.008 · Cited by 304
Self-citationRatjen, F., Munck, A., Kho, P., Angyalosi, G., & for the ELITE Study Group (2010) · Thorax · doi:10.1136/thx.2009.121657 · Cited by 291
Sousa, A., & Pereira, M. (2014) · Pathogens · doi:10.3390/pathogens3030680 · Cited by 279
Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa
Kunz Coyne, A. J., El Ghali, A., Holger, D., Rebold, N., & Rybak, M. J. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00591-2 · Cited by 275
Heijerman, H., Westerman, E., Conway, S., & Touw, D. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.04.005 · Cited by 264
Self-citationEradication of early Pseudomonas aeruginosa infection
Høiby, N., Frederiksen, B., & Pressler, T. (2005) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2005.05.018 · Cited by 255
Self-citationDeppisch, C., Herrmann, G., Graepler-Mainka, U., Wirtz, H., Heyder, S., Engel, C., Marschal, M., Miller, C. C., & Riethmüller, J. (2016) · Infection · doi:10.1007/s15010-016-0879-x · Cited by 115
Recurrent exacerbations affect FEV1 decline in adult patients with cystic fibrosis
Amadori, A., Antonelli, A., Balteri, I., Schreiber, A., Bugiani, M., & De Rose, V. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2008.09.024 · Cited by 64
Metadata
- Authors
- Döring, G., Conway, S. P., Heijerman, H. G. M., Hodson, M. E., Høiby, N., Smyth, A., Touw, D. J., & the Consensus Committee, F.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2000-10
- Volume
- 16
- Issue
- 4
- Pages
- 749
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2155069031
- Cited by
- 620
- References
- 84
- FWCI
- 16.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.